Effect of Huankuile on Colon Injury in Rats with Ulcerative Colitis by Reducing TNF-α and MMP9

Overview

Journal Eur J Med Res

Publisher Biomed Central

Specialty General Medicine

Date 2024 Feb 6

PMID 38321559

Authors

Xilinguli Wushouer

Kasimujiang Aximujiang

Nafeisha Kadeer

Abulaiti Aihemaiti

Li Zhong

Kurexi Yunusi

Affiliations

Soon will be listed here.

Abstract

Objective: To explore the mechanism of huankuile (HKL) in colon injury repair in rats with ulcerative colitis (UC).

Methods: Fifty SPF Wistar male rats were divided randomly into a normal group, a negative control group, an HKL intervention group ('HKL group') and a 5-aminosalicylic acid intervention group ('5-ASA group'). After 14 days of intervention with corresponding drugs, pathological scores were obtained using the results of immunohistochemical staining; morphological changes were observed by hematoxylin-eosin staining, and the mRNA expression levels of tumour necrosis factor-α (TNF-α), matrix metalloproteinase 9 (MMP9) and interleukin-13 (IL-13) were detected by real-time quantitative PCR.

Results: After the successful construction of the rat model, it was compared with the rats in the normal group. In the negative group, it was found that the expression of TNF-α and MMP9 was significantly increased in the colonic mucosal epithelia of the rats, the pathological score was significantly increased (P < 0.05), and the mRNA expression levels of TNF-α, MMP9 and IL-13 were increased (P < 0.05). After treatment with HKL, the colonic morphology of the rats returned to normal, the expression of TNF-α and MMP9 in the colonic mucosal epithelium of the rats returned to normal, the pathological score grade was significantly reduced (P < 0.05), and the mRNA expression levels of TNF-α, MMP9 and IL-13 were reduced; these results were largely consistent with those of the normal group, with no statistically significant difference.

Conclusion: HKL effectively improved the general symptoms and tissue injury in UC rats, and the therapeutic effect was better than that of 5-ASA group. Ulcerative colitis in rats increased the expression of TNF-α, MMP9 and IL-13. HKL repaired UC-induced colonic injury in rats by decreasing the expression of TNF-α, MMP9 and IL-13.

References

Zhong Y, Liu W, Xiong Y, Li Y, Wan Q, Zhou W . Astragaloside Ⅳ alleviates ulcerative colitis by regulating the balance of Th17/Treg cells. Phytomedicine. 2022; 104:154287. DOI: 10.1016/j.phymed.2022.154287. View

Wang X, Quan S, Li J, Liu Y, Sun H, Zhang J . Protective Effects of Grape Seed Proanthocyanidin Extract in Preventing DSS Induced Ulcerative Colitis Based on Pharmacodynamic, Pharmacokinetic and Tissue Distribution. Curr Drug Metab. 2022; 23(6):496-505. DOI: 10.2174/1389200223666220609151836. View

de Bruyn M, Arijs I, Wollants W, Machiels K, Van Steen K, Van Assche G . Neutrophil gelatinase B-associated lipocalin and matrix metalloproteinase-9 complex as a surrogate serum marker of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2014; 20(7):1198-207. DOI: 10.1097/MIB.0000000000000068. View

Singh S, George J, Boland B, Vande Casteele N, Sandborn W . Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. J Crohns Colitis. 2018; 12(6):635-643. PMC: 7189966. DOI: 10.1093/ecco-jcc/jjy004. View

Han M, Liao W, Si X, Bai C, Gai Z . Protective effects of Lacticaseibacillus rhamnosus Hao9 on dextran sulphate sodium-induced ulcerative colitis in mice. J Appl Microbiol. 2022; 133(3):2039-2049. DOI: 10.1111/jam.15665. View

Han Z, Wang H, Guo D, Zhang J . Integrative transcriptomic and metabonomic profiling analyses reveal the molecular mechanism of Chinese traditional medicine huankuile suspension on TNBS-induced ulcerative colitis. Aging (Albany NY). 2021; 13(4):5087-5103. PMC: 7950284. DOI: 10.18632/aging.202427. View

Nguyen N, Solitano V, Vuyyuru S, MacDonald J, Syversen S, Jorgensen K . Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Gastroenterology. 2022; 163(4):937-949.e2. DOI: 10.1053/j.gastro.2022.06.052. View

Han J, Kim H, Jeon K, Choi Y, Lee H, Kwon Y . Peroxisome proliferator-activated receptor-δ activates endothelial progenitor cells to induce angio-myogenesis through matrix metallo-proteinase-9-mediated insulin-like growth factor-1 paracrine networks. Eur Heart J. 2011; 34(23):1755-65. DOI: 10.1093/eurheartj/ehr365. View

Nunes N, Chandran P, Sundby M, Visioli F, Da Costa Goncalves F, Burks S . Therapeutic ultrasound attenuates DSS-induced colitis through the cholinergic anti-inflammatory pathway. EBioMedicine. 2019; 45:495-510. PMC: 6642284. DOI: 10.1016/j.ebiom.2019.06.033. View

10.

Tatiya-Aphiradee N, Chatuphonprasert W, Jarukamjorn K . Immune response and inflammatory pathway of ulcerative colitis. J Basic Clin Physiol Pharmacol. 2018; 30(1):1-10. DOI: 10.1515/jbcpp-2018-0036. View

11.

Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R . Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011; 60(5):571-607. DOI: 10.1136/gut.2010.224154. View

12.

Xuan-Qing C, Xiang-Yu L, Shi-Jia L . Baitouweng decoction alleviates dextran sulfate sodium-induced ulcerative colitis by regulating intestinal microbiota and the IL-6/STAT3 signaling pathway. J Ethnopharmacol. 2020; 265:113357. DOI: 10.1016/j.jep.2020.113357. View

13.

Cui H, Cai Y, Wang L, Jia B, Li J, Zhao S . Berberine Regulates Treg/Th17 Balance to Treat Ulcerative Colitis Through Modulating the Gut Microbiota in the Colon. Front Pharmacol. 2018; 9:571. PMC: 5991375. DOI: 10.3389/fphar.2018.00571. View

14.

Abdelhamid A, Youssef M, Cavalu S, Mostafa-Hedeab G, Youssef A, Elazab S . Carbocisteine as a Modulator of Nrf2/HO-1 and NFκB Interplay in Rats: New Inspiration for the Revival of an Old Drug for Treating Ulcerative Colitis. Front Pharmacol. 2022; 13:887233. PMC: 9214041. DOI: 10.3389/fphar.2022.887233. View

15.

Mahid S, Minor K, Soto R, Hornung C, Galandiuk S . Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006; 81(11):1462-71. DOI: 10.4065/81.11.1462. View

16.

Ko C, Singh S, Feuerstein J, Falck-Ytter C, Falck-Ytter Y, Cross R . AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology. 2018; 156(3):748-764. PMC: 6858922. DOI: 10.1053/j.gastro.2018.12.009. View

17.

Santana A, Medina C, Paz-Cabrera M, Diaz-Gonzalez F, Farre E, Salas A . Attenuation of dextran sodium sulphate induced colitis in matrix metalloproteinase-9 deficient mice. World J Gastroenterol. 2006; 12(40):6464-72. PMC: 4100636. DOI: 10.3748/wjg.v12.i40.6464. View

18.

Ananthakrishnan A . Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015; 12(4):205-17. DOI: 10.1038/nrgastro.2015.34. View

19.

Sandborn W, Bhandari B, Fogel R, Onken J, Yen E, Zhao X . Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. Aliment Pharmacol Ther. 2016; 44(2):157-69. PMC: 5089609. DOI: 10.1111/apt.13653. View

20.

Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U . Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J Crohns Colitis. 2017; 11(7):769-784. DOI: 10.1093/ecco-jcc/jjx009. View